anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides a traditional Chinese medicine composition for treating endometriosis, which takes salvia miltiorrhiza and dragon's blood as monarch drugs, removes stasis, promotes tissue regeneration, and is regulated to be later used for treating endometriosis. The zedoary, the cattail pollen charcoal, the sargentgloryvine stem, the prepared nutgrass galingale rhizome and the fried fennel are compatible, the qi and the blood are treated simultaneously, the qi circulation is followed by the blood circulation, and the blood circulation is followed by the pain relief, and the zedoary, the cattail pollen charcoal, the sargentgloryvine stem, the prepared nutgrass galingale. Radix astragali Preparata, rhizoma Dioscoreae, Coicis semen, Prunellae Spica, and radix scrophulariae are used as adjuvant drugs for removing blood stasis and promoting regeneration without impairment of healthy qi. Prepared licorice root, radix Glycyrrhizae Praeparata coordinates the effects of the other drugs in the recipe. The whole formula has the effects of activating blood and stimulating the menstrual flow, and eliminating abdominal mass and relieving pain. Has definite curative effect on endometriosis and is not easy to relapse after healing.
Intervention group will receive UCAN SuperStarch study drinks. 100g carbohydrate will be consumed the night before surgery and 50g carbohydrate will be consumed 2 - 3 hours before surgery.
A system for selecting a treatment schema based on user willingness includes at least a first computing device configured to receive at least a user constitutional datum and at least a user ailment state from at least a second computing device. At least a first computing device is configured to determine, with an adaptive machine learning module, at least a remedial process label. At least a first computing device is configured to derive a remedial attribute list, wherein the remedial attribute list further comprises a plurality of remedial attribute list entries. At least a first computing device is configured to generate a plurality of treatment schemas. At least a first computing device is configured to select a treatment schema from the plurality of treatment schemas. At least a first computing device is configured to transmit the selected treatment schema to at least a second computing device.
BACKGROUND: Misophonia is a complex condition characterized by extreme emotional distress in response to specific sounds or specific visual stimuli. Despite a growing body of clinical and neuroscientific literature, the etiology of this condition remains unclear. Hyperarousal, that is, a state of heightened alertness and disinhibition, as a core feature of misophonia is supported by behavioral and neuroimaging literature and might represent a viable clinical target for the development of both behavioral and pharmacological interventions. The aim of this study was to investigate how hyperarousal might be linked to neurocognitive processes associated with vigilance and stimulus discrimination in youth with misophonia.
METHODS: We compared 72 children and adolescents with misophonia (13.74 ± 2.44 years) (64 % female) and 89 children and adolescents with anxiety (12.35 ± 2.57 years) (58.4 % female) on behavioral and signal detection performance of the immediate memory task (IMT). Anxiety patients were used as a clinical control group to distinguish attentional processes specific for misophonia.
RESULTS: Both groups demonstrated similar behavioral performance, including response rate and reaction time. However, misophonia was associated with elevated stimulus discrimination (d prime), which in turn was positively correlated with the severity of misophonia trigger reports.
CONCLUSIONS: Our findings are in line with previous cognitive and neuroimaging studies, and support an arousal-based model of misophonia, where individuals with misophonia experience a state of heightened vigilance, being more aware of stimuli in the environment. Our findings provide a neurocognitive basis for future study of neurochemical imaging that might further progress towards clinical targets.
Yiyi decoction is a Chinese herbal formula for the treatment of acute pancreatitis that has been used in clinical practice for decades. A previous study has suggested that resveratrol, emodin, rhein and their derivatives might be the potential pharmacodynamic components in Yiyi decoction, and researchers have proposed that resveratrol, emodin and rhein are candidate markers for quality control. The present study investigated the intervention effect of Yiyi decoction and its effective components on murine acute pancreatitis using metabolomic approach that integrated global and unique metabolic characteristics. First, serum metabolomics based on the platform of ultra-high performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry was performed to assess metabolic changes in experimental acute pancreatitis. Second, an in-depth analysis of bile acid metabolism was performed based on an in-house database. Finally, an integrated analysis of the intervention effect of Yiyi decoction and its effective components in response to these metabolic perturbations was performed. As a result, 39 potential biomarkers for the pathogenesis of acute pancreatitis, mainly phospholipids, fatty acids, bile acids and lipoylcarnitines, were screened and annotated. Integrated analysis revealed that the metabolic disorders in acute pancreatitis mice were reversed by Yiyi decoction primarily via regulating glycerophospholipid metabolism, bile acid biosynthesis, carnitine synthesis and fatty acid metabolism. Yiyi decoction components may effectively target the migratory metabolome. Histopathological and biochemical analyses suggested that Yiyi decoction maintained the gut barrier function and inhibited inflammatory cytokines, thus exert anti-acute pancreatitis effects. The present study utilized an approach that integrated global and unique metabolic characteristics to elucidate the underlying mechanisms of Chinese herbal formulas from a metabolomics perspective.
Selection of the appropriate dosage strength (AUVI-Q 0.3 mg, AUVI-Q 0.15 mg or AUVI-Q 0.1 mg) is determined according to patient body weight.Selection of the appropriate dosage strength (AUVI-Q 0.3 mg, AUVI-Q 0.15 mg or AUVI-Q 0.1 mg) is determined according to patient body weight.

  * Patients greater than or equal to 30 kg (approximately 66 pounds or more): AUVI-Q 0.3 mg 
  * Patients 15 to 30 kg (33 to 66 pounds): AUVI-Q 0.15 mg 
  * Patients 7.5 to 15 kg (16.5 to 33 pounds): AUVI-Q 0.1 mg 



Inject AUVI-Q intramuscularly or subcutaneously into the anterolateral aspect of the thigh, through clothing if necessary. Instruct caregivers of young children and infants who are prescribed AUVI-Q and who may be uncooperative and kick or move during an injection to hold the child’s leg firmly in place and limit movement prior to and during an injection [ see WARNINGS AND PRECAUTIONS ( 5.2) ]. 

Each AUVI-Q contains a single dose of epinephrine for single-use injection. Since the doses of epinephrine delivered from AUVI-Q are fixed, consider using other forms of injectable epinephrine if doses lower than 0.1 mg are deemed necessary. Each AUVI-Q contains a single dose of epinephrine for single-use injection. Since the doses of epinephrine delivered from AUVI-Q are fixed, consider using other forms of injectable epinephrine if doses lower than 0.1 mg are deemed necessary. 

The prescriber should carefully assess each patient to determine the most appropriate dose of epinephrine, recognizing the life-threatening nature of the reactions for which this drug is indicated. With severe persistent anaphylaxis, repeat injections with an additional AUVI-Q may be necessary. More than two sequential doses of epinephrine should only be administered under direct medical supervision [ ]. The prescriber should carefully assess each patient to determine the most appropriate dose of epinephrine, recognizing the life-threatening nature of the reactions for which this drug is indicated. With severe persistent anaphylaxis, repeat injections with an additional AUVI-Q may be necessary. More than two sequential doses of epinephrine should only be administered under direct medical supervision [ see WARNINGS AND PRECAUTIONS ( 5.1) ]. 

The epinephrine solution in the viewing window of AUVI-Q should be inspected visually for particulate matter and discoloration. Epinephrine is light sensitive and should be stored in the outer case provided to protect it from light [ ]. The epinephrine solution in the viewing window of AUVI-Q should be inspected visually for particulate matter and discoloration. Epinephrine is light sensitive and should be stored in the outer case provided to protect it from light [ see STORAGE AND HANDLING ( 16.2) ].
The GetHealthy-OA program combines a 6-week mind-body program delivered via live video with the oral supplement fisetin. Oral fisetin will be taken for 2 consecutive days (day 1 and 2), a 28-day wash-out period, and then another 2-day course (days 31 and 32).
FIELD: medicine, pharmacology. SUBSTANCE: invention proposes hexapeptide of the structural formula: lysyl-histidyl-glycyl-lysyl-histidyl-glycine as a drug. Drug has glycine as a stabilizing agent additionally. Drug shows high effectiveness of action with respect to stimulation of humoral immunity, immune response potency and molecules of intermolecular interaction in therapy of immunodeficiency states. EFFECT: enhanced effectiveness of agent. 3 cl, 3 tbl, 5 ex
Central nervous system (CNS) tumours in neonates are relatively rare and present differently when compared with those occurring later in childhood in terms of aetiology, clinical features, location, histology and prognosis. The clinical presentation is extremely variable. Even if the most frequent clinical sign is a macrocephaly, there are many other non-specific symptoms associated. The prognosis is usually poor with overall survival of less than 30%. Surgery continues to be the primary treatment for neonatal CNS tumours, aiming for a gross total resection, directly correlated with prognosis and the overall outcome. The chemotherapy is the only adjuvant therapy whereas the radiotherapy is avoided under three years of age because of the severe sequelae. Hence the importance of molecular characterization of these neoplasms in order to improve the accuracy of the diagnosis and identify new therapeutic targets. The aim of this review is to describe the main characteristics of these tumours and the recent advances in their treatment in order to recognize these pathologies in the prenatal period and create a multidisciplinary team providing the best possible treatment while minimising the risk of long-term complications. Neonatologists play a key role in the early detection, diagnostic evaluation, management and supportive care of these neonates.  Conclusion: The aim of this review is to describe the main characteristics of these tumours and the recent advances in their treatment in order to ensure the essential knowledge that will help the neonatologist identify them and create a multidisciplinary team providing the best possible treatment while minimising the risk of long-term complications. What is Known: • Neonatal CNS tumours are relatively rare and their early identification is important to identify the best diagnostic-therapeutic management. • Surgery is the main treatment of neonatal CNS tumours. The extent of surgical resection directly correlates with prognosis and outcome. What is New: • Predisposing conditions such as Cancer Predisposition Syndromes must be considered. • Targeted drugs and other therapeutic strategies can be identified through molecular characterization.
Alzheimer's disease (AD) is the most common neurodegenerative disorder and is the most common cause of dementia. AD is characterized pathologically by proteinaceous aggregates composed of amyloid beta (Aβ) and tau as well as progressive neurodegeneration. Concurrently with the buildup of protein aggregates, a strong neuroinflammatory response, in the form of reactive astrocytosis and microgliosis, occurs in the AD brain. It has recently been shown that the gut microbiome (GMB), composed of trillions of bacteria in the human intestine, can regulate both reactive astrocytosis and microgliosis in the context of both amyloidosis and tauopathy. Many studies have implicated microglia in these processes. However, growing evidence suggests that interactions between the GMB and astrocytes have a much larger role than previously thought. In this review, we summarize evidence regarding the gut microbiome in the control of reactive astrocytosis in AD.
Temperature is one of the most prominent environmental factors that influence plant immunity. Depending on the plant-pathogen system, increased temperature may inhibit or enhance disease resistance or immunity in plants. Measuring the effect of temperature on plant immunity is the first step toward revealing climate effects on plant-pathogen interactions and molecular regulators of temperature sensitivity of plant immunity. Quantification of plant disease resistance or susceptibility under different temperatures can be accomplished by assessing pathogen growth over time in infected plants or tissues. Here, we present a protocol for quantifying pathogen growth in the most studied system of Arabidopsis thaliana and Pseudomonas syringae pathovar tomato (Pst) DC3000. We discuss important factors to consider for assaying pathogen growth in plants under different temperatures. This protocol can be used to assess temperature sensitivity of resistance in different plant genotypes and to various pathovars.
PURPOSE: To obtain a new compound having excellent antiallergic action, thus useful for treating, as an antiallergic agent, allergic diseases such as bronchial asthma, pollinosis, allergic rhinitis and endocarditis. CONSTITUTION: This new compound (salt) is expressed by formula I (R1 is benzene ring, naphthalene ring, etc.; R2 and R3 are each H or a lower alkyl), e.g. 3-[4-(2-carboethoxyphenyl)piperazinyl]-1-(2-t-butyl-4-methoxyphenyl)pr opan-2- ol. The compound of formula I is obtained by condensation reaction under heating between a 2,3epoxypropanol derivative of formula II and a 4-(2- carboalkoxyphenyl)piperazine of formula III through reflux under heating in the presence of an organic amine in a solvent. The compound of formula II is prepared, for example, from a compound of the formula R1 OH and a halomethyl oxirane. The compound of formula III is prepared, for example, by reaction between N-monobenzylpiperazine and an o-halobenzoic acid lower alkyl ester followed by catalytic reduction.
In addition to comparing the outcomes between sleeve gastrectomy and gastric bypass, the study project includes a PET trial conducted in Turku. The objectives of this PET study are to measure effect of obesity on food-stimuli mediated brain activation response and on hormones affecting both feeding and energy balance. In the second part the same variables are studied after bariatric surgery: either laparoscopic sleeve gastrectomy or Roux-en-Y gastric bypass. In addition the effect of weight loss due to bariatric surgery on glucose uptake and free fatty acid metabolism is measured. The objective is also to study whether less invasive sleeve gastrectomy is as beneficial in terms of weight loss and co-morbid diseases as more invasive Roux-en-Y gastric bypass and to compare the risk factors between these two surgical procedures. Regional glucose uptake and free fatty acid uptake in myocardium, skeletal muscle, subcutaneous fat, visceral fat, pancreas, liver and brain are studied with PET at baseline before bariatric surgery and post-operatively on the 3rd month. Changes in body fat distribution, in ectopic fat and fat content of key organs are investigated with magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS). Brain reward system response to food stimuli is assessed using functional MRI (fMRI) and white and grey matter volumes using diffusion tensor imaging (DTI).

The study consists of 80 morbidly obese adults, BMI ≥ 40 kg/m2 or if there is additional risk factor BMI ≥ 35 kg/m2. From these subjects, 40 are further studied with positron emission tomography (PET) and magnetic resonance imaging (MRI). In addition functional MRI (fMRI) will be performed for 40 subjects. For fMRI, a control group is recruited consisting of 20 lean and healthy subjects. Subjects are physically examined and anthropometric data are measured along with blood sampling.
Autologous stem cell transplant (or transplantation) ineligible DLBCL participants will receive 1 mg/kg magrolimab priming dose on Day 1 for Cyle 1 followed by maintenance doses of 30 or 45 mg/kg on Days 8, 11, 15, 22, and 29 for Cycle 1, every week for Cycle 2, and every 2 weeks for each cycle to determine maximum tolerated dose (MTD) + rituxumab 375 mg/m\^2 + gemcitabine 1000 mg/m\^2 + oxaliplatin 100 mg/m\^2. Cycle length is 28 days.
D0 + 90 days: evaluation with the 3C60 knee. A period of 10 days of "wash out". D1 + 30 days: evaluation with the non-microprocessor knee.
The MTD of vinblastine in combination with a monthly dose of carboplatin will be determined during the first cycle of therapy. Each 4-week cycle will consist of carboplatin once every 4 weeks on day 1. Vinblastine will be given once a week for 3 weeks followed by a one week break. Doses of carboplatin and vinblastine sulfate will be assigned at study enrollment. Patients may receive eleven additional four week cycles, barring tumor progression or unacceptable toxicity. The total duration of therapy will be approximately 48 weeks.
Participants received 2 grams per kilogram (g/kg) of GAMUNEX-C, which was capped to a maximum of 160 g infusion intravenously (IV) for participants weighing more than 80 kg on Day 1. The 2 g/kg net total dose was divided either into infusions of 500 mg/kg body weight over 4 days or 400 mg/kg body weight over 5 days as per investigator's decision. Participants received standard of care interventions as per Principal Investigator's discretion from Day 1 up to Day 29.
Procedure for the obtaining of 5- (3 '' - dimethylamin propylidene) dibenzo (a, b) (1.4) cicloheptadieno chlorhydrate. It consists of the reaction and the dibenzo (a, d) (1.4) cicloheptadien-5-ona with the magnesium of chlorropropildimethylamine in tetrahydrofuran to reflux to obtain the compound of formula (I). This is separated and treated with acetic anhydroid to reflux, after which the acetic anhydride is destified and the waste is threw with sodium hydroxide and extracted with ether. Ethernaus dissolution is the satura with a current of hydrogen global chloride, which precipits the corresponding chlorhydrate. This composite has a therapeutic application as a muscle relaxant. (Machine-translation by Google Translate, not legally binding)
Process for the fixation of biological molecules on magnetic supports by contacting a soln. contg. the biological molecules to be fixed with a magnetic support based on vinylaromatic polymer particles. When the molecules have been adsorbed, the support is sepd. from the soln. Pref. the vinylaromatic polymers are obtd. by suspension polymerisation of the vinylaromatic cpd. alone or in mixt. with a copolymerisable monomer in the presence of an initiator, a suspension agent and a magnetic charge e.g. ferrite or magnetite particles. The magnetic charge is dispersed in a soln. of the homo- or copolymer or the monomer(s) and the obtd. dispersion is suspended in water and the monomer(s) polymerised. The obtd. biological support is used in immunoenzymatic, radioimmunological or fluorimetry determinations or in determination using other markers. The process may also be used to separate biological substances, e.g. proteins such as bacteria, viruses, cells, antigens and antibodies. Examples of biological molecules fixed to the polymers are DNA, bovine serum albumin, rabbit Ig, Herpes antigen and Candida albicans antigen which may be used to detect the antigens.
Patients in the placebo arm will follow the same titration schedule as those in the active arm. Patients will titrate up to target dose by starting 40mg capsules: 1 capsule daily for 14 days. Following study visit 3 (after 2 weeks on the titration dose), patients will increase the dose to 80mg daily.
Knee osteoarthritis (OA) pain is an important source of morbidity and cost to the health care system. Over 60,000 knee replacement surgeries are performed in Canada every year, making it the second most common surgery. Our institution (St. Joseph's Healthcare Hamilton) is the first hospital in Canada to purchase a Mako RIO orthopaedic robot to assist with performing knee replacements. The knee is divided into three compartments, and one, two, or all three compartments can become arthritic. Over 90% of patients with end-stage knee OA receive a total knee replacement (also known as total knee arthroplasty or TKA) even if they have one or two healthy knee compartments. Partial knee replacements are an option for these patients but these procedures are very technically demanding and associated with a higher risk of implant failure. For this reason, few surgeons are experts at partial knee replacements. We believe that we can use robotic technology to make it easier for surgeons to perform partial replacements more accurately, thereby increasing the quality and survivorship of partial knee replacements. This may lead to better patient-important outcomes like return to activity, pain, and satisfaction, and eventually better access to high-quality partial knee replacements for Canadians. This will be the first study to evaluate total knee replacements (standard care) versus robot-assisted partial knee replacements, and could lead to greater uptake of robotic technology in orthopaedics and a shift toward anatomy-sparing partial knee replacements.
The present invention provides a surgical extraction system for communicating between a smoke evacuation device and a filter device via a communication circuit. The surgical evacuation system includes a smoke evacuation device including a pump and a motor operably coupled to the pump. The surgical evacuation system also includes a communication circuit and a filter device in communication with the smoke evacuation device via the communication circuit. The filter device includes a plurality of filter components including a plurality of filter elements and a plurality of filter sensors. The plurality of filter elements includes at least one of a fluid filter, a particulate filter, and a charcoal filter. The communication circuit is configured to be capable of: authenticating a plurality of filter components; verifying a remaining life of at least one filter component of the plurality of filter components; updating parameters output from the plurality of filter components; and recording errors output from the plurality of filter components.
PURPOSE: Full-thickness retracted massive supraspinatus tears are a challenge for arthroscopic surgeons where multiple options for treatment exist, but medializing the attachment is a relatively easy procedure for which a decision can be taken intraoperatively. We investigate the viability of MATERIAL AND METHODS: Ten freshly thawed cadavers were taken and dissected. The supraspinatus tendon was resected, and then its attachment was progressively medialized. The range of motion (abduction, internal and external rotation) was recorded and compared. As a result, we noted a statistically significant decrease in abduction, internal and external rotation with progressive medialization of the supraspinatus insertion.
CONCLUSION: Medialized repair of the supraspinatus can be performed only to an extent beyond which it compromises glenohumeral motion. We noted a statistically significant decrease in ROM with even a 3 mm medialization of the tendon, but the acceptable medialization has to be determined on a case-to-case basis.